JP2013500324A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013500324A5 JP2013500324A5 JP2012522250A JP2012522250A JP2013500324A5 JP 2013500324 A5 JP2013500324 A5 JP 2013500324A5 JP 2012522250 A JP2012522250 A JP 2012522250A JP 2012522250 A JP2012522250 A JP 2012522250A JP 2013500324 A5 JP2013500324 A5 JP 2013500324A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- fulvestrant
- dose
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- VWUXBMIQPBEWFH-WCCTWKNTSA-N (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 3
- 229960002258 Fulvestrant Drugs 0.000 claims 3
- 229940034984 ENDOCRINE THERAPY ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS Drugs 0.000 claims 2
- 239000003886 aromatase inhibitor Substances 0.000 claims 2
- 238000009261 endocrine therapy Methods 0.000 claims 2
- 102000015694 estrogen receptors Human genes 0.000 claims 2
- 108010038795 estrogen receptors Proteins 0.000 claims 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- 229960001603 Tamoxifen Drugs 0.000 claims 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 1
- 229960002932 anastrozole Drugs 0.000 claims 1
- 229960000255 exemestane Drugs 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- 102000003998 progesterone receptors Human genes 0.000 claims 1
- 108090000468 progesterone receptors Proteins 0.000 claims 1
Claims (8)
- 内分泌療法で進行または再発した閉経後進行乳癌女性の処置で使用するために投与量５００ｍｇのフルベストラントを月１回投与するための、フルベストラントを含む医薬組成物。
- ５００ｍｇの追加的用量を処置の最初の１カ月の間に投与する、請求項１に記載の医薬組成物。
- 追加的用量を約１４日目に投与する、請求項２に記載の医薬組成物。
- 女性がエストロゲン受容体陽性またはプロゲステロン受容体陽性である、請求項１〜３のいずれかに記載の医薬組成物。
- 女性がエストロゲン受容体陽性である、請求項４に記載の医薬組成物。
- 内分泌療法での進行または再発が、タモキシフェンまたはアロマターゼ阻害剤での治療を含んでいた、請求項１〜５のいずれかに記載の医薬組成物。
- アロマターゼ阻害剤が、アナストロゾール、レトロゾールまたはエキセメスタンから選択される、請求項６に記載の医薬組成物。
- 投与量２５０ｍｇでのフルベストラントと比較して無増悪期間を増大させる、請求項１〜７のいずれかに記載の医薬組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0912999.0 | 2009-07-27 | ||
| GBGB0912999.0A GB0912999D0 (en) | 2009-07-27 | 2009-07-27 | Method-803 |
| PCT/GB2010/051228 WO2011012885A1 (en) | 2009-07-27 | 2010-07-26 | Fulvestrant in a dosage of 500mg for the treatment of advanced breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013500324A JP2013500324A (ja) | 2013-01-07 |
| JP2013500324A5 true JP2013500324A5 (ja) | 2013-06-27 |
Family
ID=41066853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012522250A Pending JP2013500324A (ja) | 2009-07-27 | 2010-07-26 | 進行乳癌の処置のための投与量５００ｍｇでのフルベストラント |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US20120214778A1 (ja) |
| EP (1) | EP2459199A1 (ja) |
| JP (1) | JP2013500324A (ja) |
| KR (1) | KR20120042843A (ja) |
| AT (1) | AT510868A2 (ja) |
| AU (1) | AU2010277373A1 (ja) |
| BG (1) | BG111123A (ja) |
| BR (1) | BR112012001837A2 (ja) |
| CA (1) | CA2768286A1 (ja) |
| CL (1) | CL2012000226A1 (ja) |
| CZ (1) | CZ201235A3 (ja) |
| DE (1) | DE112010003084T5 (ja) |
| DK (1) | DK201270089A (ja) |
| EA (1) | EA201200190A1 (ja) |
| EC (1) | ECSP12011629A (ja) |
| EE (1) | EE201200003A (ja) |
| ES (1) | ES2393323A1 (ja) |
| FI (1) | FI20125207L (ja) |
| GB (2) | GB0912999D0 (ja) |
| HR (1) | HRP20120084A2 (ja) |
| HU (1) | HUP1200203A3 (ja) |
| IL (1) | IL217527A0 (ja) |
| IS (1) | IS8994A (ja) |
| LT (1) | LT5953B (ja) |
| MX (1) | MX2012001282A (ja) |
| NO (1) | NO20120147A1 (ja) |
| PE (1) | PE20121177A1 (ja) |
| PL (1) | PL399129A1 (ja) |
| RO (1) | RO128705A2 (ja) |
| RS (1) | RS20120022A1 (ja) |
| SE (1) | SE1250155A1 (ja) |
| SG (1) | SG177586A1 (ja) |
| SK (1) | SK500052012A3 (ja) |
| TR (1) | TR201200950T1 (ja) |
| WO (1) | WO2011012885A1 (ja) |
| ZA (1) | ZA201201406B (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| MA40271A (fr) * | 2014-05-21 | 2017-03-29 | Hoffmann La Roche | Procédés pour traiter le cancer du sein luminal a pr-positif, avec un inhibiteur de pi3k, pictilisib |
| US20190147986A1 (en) * | 2016-05-17 | 2019-05-16 | Abraxis Bioscience, Llc | Methods for assessing neoadjuvant therapies |
| AU2016427261B2 (en) * | 2016-10-21 | 2022-10-06 | Crescita Therapeutics Inc. | Pharmaceutical compositions |
| US20180153868A1 (en) * | 2016-12-06 | 2018-06-07 | Gilead Sciences, Inc. | Treatment of breast cancer by concomitant administration of a bromodomain inhibitor and a second agent |
| KR102267378B1 (ko) * | 2019-09-10 | 2021-06-21 | 가천대학교 산학협력단 | C12, c16 또는 c18-세라마이드를 유효성분으로 함유하는 유방암 예방 또는 치료용 약학적 조성물 |
-
2009
- 2009-07-27 GB GBGB0912999.0A patent/GB0912999D0/en not_active Ceased
-
2010
- 2010-07-26 PL PL399129A patent/PL399129A1/pl not_active Application Discontinuation
- 2010-07-26 DE DE112010003084T patent/DE112010003084T5/de not_active Withdrawn
- 2010-07-26 RO ROA201200064A patent/RO128705A2/ro unknown
- 2010-07-26 KR KR1020127001388A patent/KR20120042843A/ko not_active Application Discontinuation
- 2010-07-26 US US13/387,584 patent/US20120214778A1/en not_active Abandoned
- 2010-07-26 PE PE2012000120A patent/PE20121177A1/es not_active Application Discontinuation
- 2010-07-26 JP JP2012522250A patent/JP2013500324A/ja active Pending
- 2010-07-26 SK SK50005-2012A patent/SK500052012A3/sk not_active Application Discontinuation
- 2010-07-26 EA EA201200190A patent/EA201200190A1/ru unknown
- 2010-07-26 SG SG2012001632A patent/SG177586A1/en unknown
- 2010-07-26 GB GB1201486.6A patent/GB2484050A/en not_active Withdrawn
- 2010-07-26 EE EEP201200003A patent/EE201200003A/xx unknown
- 2010-07-26 AT ATA9259/2010A patent/AT510868A2/de not_active Application Discontinuation
- 2010-07-26 ES ES201290002A patent/ES2393323A1/es active Pending
- 2010-07-26 EP EP10752117A patent/EP2459199A1/en not_active Withdrawn
- 2010-07-26 BR BR112012001837A patent/BR112012001837A2/pt not_active IP Right Cessation
- 2010-07-26 HU HU1200203A patent/HUP1200203A3/hu unknown
- 2010-07-26 CZ CZ20120035A patent/CZ201235A3/cs unknown
- 2010-07-26 MX MX2012001282A patent/MX2012001282A/es not_active Application Discontinuation
- 2010-07-26 CA CA2768286A patent/CA2768286A1/en not_active Abandoned
- 2010-07-26 AU AU2010277373A patent/AU2010277373A1/en not_active Abandoned
- 2010-07-26 SE SE1250155A patent/SE1250155A1/sv not_active Application Discontinuation
- 2010-07-26 RS RS20120022A patent/RS20120022A1/en unknown
- 2010-07-26 TR TR2012/00950T patent/TR201200950T1/xx unknown
- 2010-07-26 WO PCT/GB2010/051228 patent/WO2011012885A1/en active Application Filing
-
2012
- 2012-01-12 IL IL217527A patent/IL217527A0/en unknown
- 2012-01-18 BG BG10111123A patent/BG111123A/bg unknown
- 2012-01-24 HR HR20120084A patent/HRP20120084A2/hr not_active Application Discontinuation
- 2012-01-24 LT LT2012006A patent/LT5953B/lt not_active IP Right Cessation
- 2012-01-26 CL CL2012000226A patent/CL2012000226A1/es unknown
- 2012-01-27 EC EC2012011629A patent/ECSP12011629A/es unknown
- 2012-02-14 NO NO20120147A patent/NO20120147A1/no not_active Application Discontinuation
- 2012-02-23 FI FI20125207A patent/FI20125207L/fi not_active Application Discontinuation
- 2012-02-24 IS IS8994A patent/IS8994A/is unknown
- 2012-02-24 DK DKPA201270089A patent/DK201270089A/da not_active Application Discontinuation
- 2012-02-24 ZA ZA2012/01406A patent/ZA201201406B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017039771A5 (ja) | ||
| JP2013500324A5 (ja) | ||
| JP2018514593A5 (ja) | ||
| JP2011518883A5 (ja) | ||
| RU2017140674A (ru) | Способы лечения рака | |
| PH12013502291A1 (en) | Dhea compositions for treating menopause | |
| RU2013118325A (ru) | Лечение рака молочной железы | |
| JP2016528246A5 (ja) | ||
| IN2012DN04867A (ja) | ||
| HRP20210572T1 (hr) | Kombinacijsko liječenje raka | |
| JP2015500225A5 (ja) | ||
| Goyeneche et al. | Antiprogestins in gynecological diseases | |
| MX338290B (es) | Tratamiento de enfermedad de alzheimer, perdida de cognición, perdida de memoria y demencia con precursores de esteroides sexuales en conbinación con moduladores selectivos del receptor de estrógenos. | |
| JP2013542190A5 (ja) | ||
| JP2017516802A5 (ja) | ||
| RU2017116070A (ru) | Способ лечения первичного гормонорезистентного эндометриального рака и рака груди | |
| PE20200444A1 (es) | Terapia de combinacion para cancer de prostata | |
| JP2019529581A5 (ja) | ||
| JP2019526632A5 (ja) | ||
| LT2012006A (lt) | 500 mg dozės fulvestrantas, skirtas išplitusio krūties vėžio gydymui | |
| Ruan et al. | Breast cancer risk during hormone therapy: experimental versus clinical data | |
| RU2015139515A (ru) | Комбинированное лечение | |
| JP2019501957A5 (ja) | ||
| WO2019017497A1 (en) | USE OF CYCLIN-DEPENDENT KINASE ERIBULINE AND INHIBITORS IN THE TREATMENT OF CANCER | |
| CL2015003014A1 (es) | Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas. |